Further Questioning of the Significance of the Gepants
- PMID: 31710109
- DOI: 10.1111/head.13672
Further Questioning of the Significance of the Gepants
Comment in
-
Further Questioning of the Significance of the Gepants: A Response.Headache. 2019 Nov;59(10):1831. doi: 10.1111/head.13683. Headache. 2019. PMID: 31710110 No abstract available.
Comment on
-
The Emperor's New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful?Headache. 2019 Jan;59(1):113-117. doi: 10.1111/head.13444. Epub 2018 Nov 19. Headache. 2019. PMID: 30451300 Review. No abstract available.
References
-
- Tfelt-Hansen P, Loder E. The emperor's new Gepants: Are the effects of the new oral CGRP antagonists clinically meaningful? Headache. 2018;59:113-117.
-
- Fragility Index Calculator. Available at: https://clincalc.com.
-
- Walsh M, Srinathan S, McAuley D, et al. The statistical significance of randomized controlled trial results is frequently fragile: A case for a fragility index. J Clin Epidemiol. 2014;67:622-628.
-
- Lipton R, Conway C, Stock E, et al. Efficacy, safety, and tolerability of Rimegepant 75 mg, an oral CGRP receptor antagonist, for the acute treatment of migraine: Results from a phase 3, double-blind, randomized, placebo-controlled trial, study 301. Biohaven Pharmaceuticals. Available at: https://www.biohavenpharma.com/sites/default/files/documents/Rimegepant-....
-
- Lipton R, Croop R, Stock E, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381:142-149.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
